T E Buffart
Overview
Explore the profile of T E Buffart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Berg K, Schaap D, Voogt E, Buffart T, Verheul H, de Groot J, et al.
BMC Cancer
. 2022 Sep;
22(1):957.
PMID: 36068495
Background: The presence of mesorectal fascia (MRF) invasion, grade 4 extramural venous invasion (EMVI), tumour deposits (TD) or extensive or bilateral extramesorectal (lateral) lymph nodes (LLN) on MRI has been...
2.
Rijsemus C, Kok N, Aalbers A, Buffart T, Fijneman R, Snaebjornsson P, et al.
Eur J Radiol
. 2022 Mar;
149:110225.
PMID: 35255321
Introduction: MRI improves the selection of patients with colorectal cancer (CRC) and peritoneal metastases (PM) for cytoreductive surgery by accurately assessing the extent of PM reflected as the peritoneal cancer...
3.
Neerincx M, Sie D, van de Wiel M, van Grieken N, Burggraaf J, Dekker H, et al.
Oncogenesis
. 2015 Oct;
4:e170.
PMID: 26436952
MicroRNAs (miRs) have been recognized as promising biomarkers. It is unknown to what extent tumor-derived miRs are differentially expressed between primary colorectal cancers (pCRCs) and metastatic lesions, and to what...
4.
van Grieken N, Aoyama T, Aoyma T, Chambers P, Bottomley D, Ward L, et al.
Br J Cancer
. 2013 Mar;
108(7):1495-501.
PMID: 23511561
Background: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to...
5.
Brosens R, Belt E, Haan J, Buffart T, Carvalho B, Grabsch H, et al.
Cell Oncol (Dordr)
. 2011 Jul;
34(3):215-23.
PMID: 21717218
Background: Around 30% of all stage II colon cancer patients will relapse and die of their disease. At present no objective parameters to identify high-risk stage II colon cancer patients,...
6.
Haan J, Buffart T, Eijk P, van de Wiel M, van Wieringen W, Howdle P, et al.
Ann Oncol
. 2011 May;
23(2):367-74.
PMID: 21586687
Background: Small bowel adenocarcinoma (SBA) is a rare cancer and consequently, the options for clinical trials are limited. As they are treated according to either a colorectal or a gastric...
7.
Brosens R, Belt E, Haan J, Buffart T, Carvalho B, Grabsch H, et al.
Anal Cell Pathol (Amst)
. 2010 Oct;
33(2):95-104.
PMID: 20966546
Background: Around 30% of all stage II colon cancer patients will relapse and die of their disease. At present no objective parameters to identify high-risk stage II colon cancer patients,...
8.
Belien J, Buffart T, Gill A, Broeckaert M, Quirke P, Meijer G, et al.
Br J Cancer
. 2009 Sep;
101(6):1011-8.
PMID: 19738619
Background: DNA aneuploidy reflects gross genomic changes. It can be measured by flow cytometry (FCM-DNA) or image cytometry (ICM-DNA). In gastric cancer, the prevalence of DNA aneuploidy has been reported...
9.
Postma C, Koopman M, Buffart T, Eijk P, Carvalho B, Peters G, et al.
Ann Oncol
. 2009 Jan;
20(6):1048-56.
PMID: 19150955
Background: Colorectal cancer (CRC) is biologically a heterogeneous disease, which may affect response to drug therapy. We investigated the correlation of genome-wide DNA copy number profiles of primary tumors with...
10.
Buffart T, Overmeer R, Steenbergen R, Tijssen M, van Grieken N, Snijders P, et al.
Br J Cancer
. 2008 Nov;
99(11):1802-7.
PMID: 19002170
T-lymphocyte maturation associated protein, MAL, has been described as a tumour-suppressor gene with diagnostic value in colorectal and oesophageal cancers, and can be inactivated by promoter hypermethylation. The aim of...